Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Aug 27;56(9):e00424-18.
doi: 10.1128/JCM.00424-18. Print 2018 Sep.

Laboratory Diagnosis of Neurocysticercosis (Taenia solium)

Hector H Garcia  1   2 , Seth E O'Neal  3 , John Noh  4 , Sukwan Handali  4 ; Cysticercosis Working Group in Peru
Collaborators, Affiliations
Review

Laboratory Diagnosis of Neurocysticercosis (Taenia solium)

Hector H Garcia et al. J Clin Microbiol. .

Abstract

Neurocysticercosis accounts for approximately 30% of all epilepsy cases in most developing countries. The immunodiagnosis of cysticercosis is complex and strongly influenced by the course of infection, the disease burden, the cyst location, and the immune response of the host. The main approach to immunodiagnosis should thus be to evaluate whether the serological results are consistent with the diagnosis suggested by imaging. Antibody detection is performed using lentil lectin-purified parasite antigens in an enzyme-linked immunoelectrotransfer blot format, while antigen detection uses a monoclonal antibody-based enzyme-linked immunosorbent assay (ELISA). Promising new assay configurations have been developed for the detection of both antibody and antigen, including assays based on synthetic or recombinant antigens that may reduce costs and improve assay reproducibility and multiplex bead-based assays that may provide simultaneous quantitative results for several target antigens or antibodies.

Keywords: EITB; ELISA; Peru; Taenia solium; Western blot; antibody; antigen; cysticercosis; neurocysticercosis.

PubMed Disclaimer

Figures

FIG 1
FIG 1
Macroscopic views of cysticerci in different stages of involution.
FIG 2
FIG 2
Basal subarachnoid neurocysticercosis (magnetic resonance imaging).
FIG 3
FIG 3
Sustained EITB response despite sequential (2-fold) dilutions of a strong positive serum sample.
See this image and copyright information in PMC

References

    1. Garcia HH, Nash TE, Del Brutto OH. 2014. Clinical symptoms, diagnosis, and treatment of neurocysticercosis. Lancet Neurol 13:1202–1215. doi:10.1016/S1474-4422(14)70094-8. - DOI - PMC - PubMed
    1. Newton CR, Garcia HH. 2012. Epilepsy in poor regions of the world. Lancet 380:1193–1201. doi:10.1016/S0140-6736(12)61381-6. - DOI - PubMed
    1. Ndimubanzi PC, Carabin H, Budke CM, Nguyen H, Qian YJ, Rainwater E, Dickey M, Reynolds S, Stoner JA. 2010. A systematic review of the frequency of neurocysticercosis with a focus on people with epilepsy. PLoS Negl Trop Dis 4:e870. doi:10.1371/journal.pntd.0000870. - DOI - PMC - PubMed
    1. O'Neal SE, Flecker RH. 2015. Hospitalization frequency and charges for neurocysticercosis, United States, 2003–2012. Emerg Infect Dis 21:969–976. doi:10.3201/eid2106.141324. - DOI - PMC - PubMed
    1. Yoshino K. 1933. Studies on the post-embryonal development of Taenia solium: III. On the development of Cysticercus cellulosae within the definitive intermediate host. J Med Assoc Formosa 32:166–169.

MeSH terms

LinkOut - more resources